Intelligence Platform

Patents

Browse 20 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 12410249

Low dose antibody-based methods for treating hematologic malignancies

Actinium Phamaceuticals, Inc. · Granted Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12133849

Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha- emitting

Actinium Phamaceuticals, Inc. · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12083192

Methods for treatment of patients with myelodysplastic syndromes

Actinium Phamaceuticals, Inc. · Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11981741

Humanized anti-CD45 antibodies

Actinium Phamaceuticals, Inc. · Granted Tue May 14 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11975081

Bifunctional chelators and conjugates

Actinium Phamaceuticals, Inc. · Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11964948

Bifunctional chelators and conjugates

Actinium Phamaceuticals, Inc. · Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11912780

Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell

Actinium Phamaceuticals, Inc. · Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11844799

Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting r

Actinium Phamaceuticals, Inc. · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11406724

Stabilized radiolabeled anti-CD45 immunoglobulin compositions

Actinium Phamaceuticals, Inc. · Granted Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11364235

Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting r

Actinium Phamaceuticals, Inc. · Granted Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11292835

Low dose antibody-based methods for treating hematologic malignancies

Actinium Phamaceuticals, Inc. · Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11241512

Stabilized radio-labeled anti-CD45 immunoglobulin compositions

Actinium Phamaceuticals, Inc. · Granted Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10736975

Infusion administration of conjugated monoclonal antibodies

Actinium Phamaceuticals, Inc. · Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10420851

Stabilized radiolabeled anti-CD45 immunoglobulin compositions

Actinium Phamaceuticals, Inc. · Granted Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9790573

Method for purification of 225AC from irradiated 226RA-targets

Actinium Phamaceuticals, Inc. · Granted Tue Oct 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9603954

Methods for generating radioimmunoconjugates

Actinium Phamaceuticals, Inc. · Granted Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9534277

Method for purification of 225AC from irradiated 226RA-targets

Actinium Phamaceuticals, Inc. · Granted Tue Jan 03 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8349391

Radium target and method for producing it

Actinium Phamaceuticals, Inc. · Granted Tue Jan 08 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 03 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7374936

Method and means for site directed therapy

Actinium Phamaceuticals, Inc. · Granted Tue May 20 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 15 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 6403771

Method and means for site directed therapy

Actinium Phamaceuticals, Inc. · Granted Tue Jun 11 2002 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

expired